Maravai LifeSciences (MRVI) Misses Q4 EPS by 2c

Maravai LifeSciences (NASDAQ: MRVI) reported Q4 EPS of ($0.06), $0.02 worse than the analyst estimate of ($0.04). Revenue for the quarter came in at $56.6 million versus the consensus estimate of $56.67 million.

Financial Guidance for 2025

Maravai intends to provide certain financial guidance for 2025 during its financial results conference call on March 20, 2025 at 2:00 p.m. Pacific Time.

For earnings history and earnings-related data on Maravai LifeSciences (MRVI) click here.

You May Also Be Interested In

• Morgan Stanley upgrades CDW on stronger AI-driven server demand
• Creatd files Form S-1 and reports Q1 2026 financial results
• Pelican Way Research shorts Hyliion Holdings (HYLN) on VFG deal concerns